Variants in ASK1 Are Associated With Skeletal Muscle ASK1 Expression, In Vivo Insulin Resistance, and Type 2 Diabetes in Pima Indians

Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, Arizona, USA.
Diabetes (Impact Factor: 8.47). 02/2010; 59(5):1276-82. DOI: 10.2337/db09-1700
Source: PubMed

ABSTRACT Prior genome-wide association and exon array expression studies both provided suggestive evidence that apoptosis signal regulating kinase 1 (ASK1) may influence in vivo insulin action in Pima Indians. Genetic variants in or near ASK1 were analyzed to assess the role of this gene in insulin action and type 2 diabetes.
Genotypic data from 31 variants were used to determine the linkage disequilibrium pattern across ASK1 in Pima Indians. Eight tag SNPs were initially genotyped in 3,501 full-heritage Pima Indians. Replication for association with diabetes was assessed in a second population-based sample of 3,723 Native Americans and the published DIAGRAM study. Quantitative traits were analyzed in 536 nondiabetic Native Americans, and ASK1 expression was examined in skeletal muscle of 153 nondiabetic Native Americans.
Three tag SNPs were associated with type 2 diabetes (rs35898099, P = 0.003, odds ratio [95% CI] 1.27 [1.08-1.47]; rs1570056, P = 0.007, 1.19 [1.05-1.36]; rs7775356, P = 0.04, 1.14 [1.01-1.28]) in the full-heritage Pima Indians. The association with rs35898099 was replicated in a second sample of Native Americans (P = 0.04, 1.22 [1.01-1.47]), while that for rs1570056 was replicated in the DIAGRAM study of Caucasians (Z statistic based P = 0.026; fixed-effect model, 1.06 [1.00-1.12]). The diabetes risk allele for rs1570056 was associated with reduced insulin action as assessed by either HOMA-IR in 2,549 nondiabetic full-heritage Pima Indians (P = 0.027) or a hyperinsulinemic-euglycemic clamp among 536 nondiabetic Native Americans (P = 0.02). Real-time PCR identified a positive correlation between ASK1 expression in skeletal muscle biopsies and in vivo insulin action (P = 0.02, r = 0.23), and the risk allele for rs1570056 was associated with lower ASK1 expression (P = 0.003, r = -0.22).
ASK1 variants may increase susceptibility to type 2 diabetes by decreasing insulin sensitivity via reduced ASK1 expression.

  • [Show abstract] [Hide abstract]
    ABSTRACT: GdCl3 (gadoliniumchloride) can reduce blood glucose, however, the underlying mechanism remains unclear. Liver gluconeogenesis is an important pathway involved in the maintenance of glucose homeostasis. The aim of the present study was to investigate the role of GdCl3 on hepatic gluconeogenesis and explore the precisemolecular mechanism. A classical Type 2 diabetic mouse model, created by exposing C57BL/6J mice to a high fat diet for 4 months, was treated with GdCl3 or saline. Bodyweight, blood glucose, and insulin sensitivity were monitored. It was observed that GdCl3 significantly reduced blood glucose levels and improved insulin sensitivity. Pyruvate tolerance test further showed that GdCl3 could suppress gluconeogenesis ofdiabetic mice. And in the livers of GdCl3 treated-mice, the expression of Pepck (phosphoenolpyruvate carboxykinase) and G6pase (glucose-6-phosphatase), the key enzymes for gluconeogenesis exhibited an outstanding reduction. Furthermore,experiments in hepatocarcinoma cells revealed that GdCl3 could activate the Akt pathway to promote the phosphorylation of FoxO1, leading to the suppression of gluconeogenesis by reducing the expression of PEPCK and G6Pase, resulting indecreased cellular production of glucose. Comparable results were observed in the livers of GdCl3-treated mice. In addition, it was demonstrated that GdCl3 augmented the role of insulin to control hepatic glucose production. We conclude that GdCl3 reduces hyperglycaemia via Akt/FoxO1-induced suppression of hepaticgluconeogenesis, both in Type 2 diabetic mice (in vivo) and in hepatocarcinoma cells (in vitro), suggesting that GdCl3 may be a potential therapeutic target for diabetes.
    Clinical Science 01/2014; DOI:10.1042/CS20130670 · 5.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: With rapidly increasing prevalence, diabetes has become one of the major causes of mortality worldwide. According to the latest studies, genetic information makes substantial contributions towards the prediction of diabetes risk and individualized antidiabetic treatment. To date, approximately 70 susceptibility genes have been identified as being associated with type 2 diabetes (T2D) at a genome-wide significant level (P < 5 × 10(-8)). However, all the genetic loci identified so far account for only about 10% of the overall heritability of T2D. In addition, how these novel susceptibility loci correlate with the pathophysiology of the disease remains largely unknown. This review covers the major genetic studies on the risk of T2D based on ethnicity and briefly discusses the potential mechanisms and clinical utility of the genetic information underlying T2D.
    BioMed Research International 04/2014; 2014:926713. DOI:10.1155/2014/926713 · 2.71 Impact Factor
  • Canadian Journal of Diabetes 04/2013; 37:S191–S196. DOI:10.1016/j.jcjd.2013.01.046 · 0.46 Impact Factor

Full-text (2 Sources)

Available from
Jul 23, 2014